Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Hospital Study Fuels Debate On Motives Behind Program Expansion

This article was originally published in The Pink Sheet Daily

Executive Summary

A study published in Health Affairs finds that 340B hospitals and affiliated clinics registered in recent years have been in wealthier communities than previously. The authors believe the results support manufacturers’ allegation that the drug discount program is migrating to “one that enriches hospitals and their affiliated clinics.”

You may also be interested in...



340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs

A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.

Gaming 340B: Sen. Grassley Wants Answers On How A Hospital Bends Drug Discount Rules

The ranking member on the Senate Judiciary Committee sends a letter to the University of Alabama Hospital seeking details on how it has changed the admission status and treatment of patients to get 340B drug discounts for patients who would not have been eligible otherwise.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

UsernamePublicRestriction

Register

PS076594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel